Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed.
At Myriant, we know there`s a better, greener way to produce the products people use every day. And we`re realizing that vision—displacing barrels of petroleum by manufacturing and selling high-value chemicals made from renewable, sustainable feedstocks. As companies and consumers look for ways to reduce their carbon footprint and transition away from petroleum`s price volatility, Myriant has the solution: our proven technology platform and strategic feedstock selection enable Myriant to deliver high-quality, high-performing, green chemicals at a competitive, more-predictable cost versus petroleum-based chemicals without the need for government subsidies. That`s what we call a sustainable advantage.
Ambit Biosciences is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmaSeq is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything we do; with a focus on enhancing the lives of patients, families, physicians, providers and in payors through commercialization of products in the areas of pain and neurology, and developing drugs in areas of unmet medical needs. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain Business and has an emerging Specialty Business focused on orphan drug indications and areas of unmet medical need. Depomed has a clear THREE PILLAR strategy for growth: MAINTAIN a strong/profitable NUCYNTA franchise through a commercialization agreement with Collegium, GROW the Neurology and Pain Business and BUILD a new Specialty Business through a recent Cosyntropin transaction. The company`s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. As part of the transformation strategy, Depomed will be relocating its headquarters out of California. Information about location will be shared during the interview process. Depomed is listed on the NASDAQ market under the ticker DEPO. Depomed is an AA/EEO/Veterans/Disabled employer.